Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Humanigen Inc (HGEND)

Humanigen Inc (HGEND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN” AccessWire - Thu Sep 17, 2020

BURLINGAME, CA / ACCESSWIRE / September 17, 2020 / Humanigen, Inc. ("Humanigen") (OTCQB:HGEND)(NASDAQ:HGEN), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response...

JPM : 190.51 (-0.60%)
HGEND : 10.4000 (+15.56%)
HGEN : 0.0002 (-84.62%)
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN” Business Wire - Thu Sep 17, 2020

Humanigen, Inc. (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab,...

HGEND : 10.4000 (+15.56%)
HGEN : 0.0002 (-84.62%)
Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on Nasdaq Business Wire - Tue Sep 15, 2020

Humanigen, Inc. (HGEND) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate...

HGEND : 10.4000 (+15.56%)
Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on NASDAQ AccessWire - Tue Sep 15, 2020

BURLINGAME, CA / ACCESSWIRE / September 15, 2020 / Humanigen, Inc. (OTCQB:HGEND) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

JPM : 190.51 (-0.60%)
HGEND : 10.4000 (+15.56%)
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab AccessWire - Tue Sep 15, 2020

- Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020 - Commercial manufacturing to begin in 2021 at Lonza's manufacturing facility at...

GILD : 64.78 (-0.84%)
HGEND : 10.4000 (+15.56%)

Barchart Exclusives

Earnings, the Yen and Other Key Things to Watch This Week Barchart - Sun May 5, 2:00PM CDT
This week is relatively quiet on the news front, but there are still earnings due out and plenty of other macro factors to watch. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot